News

South Korean biopharmaceutical company Celltrion Healthcare has secured European Commission (EC) marketing authorisation for the sale of Yuflyma (CT-P17) for the treatment of multiple chronic inflammatory diseases. Yuflyma

The three partner sites in London, Southampton and Bristol. Building on earlier studies of the vaccine that have shown that it is safe, produces strong immune system responses and

Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics. The acquisition is

Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine

The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to

The US Food and Drug Administration (FDA) has approved Libtayo to be used for the treatment of patients having two of the most common skin cancers in the

Novartis has announced that the novel investigational treatment asciminib, specifically targeting the ABL myristoyl pocket (STAMP), has been awarded Breakthrough Therapy designation (BTD) by the US Food and

Global biopharmaceutical company Bristol Myers Squibb (BMS) has received  US Food and Drug Administration (USFDA) approval for its new CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi

Once the authorisation is issued, Johnson & Johnson plans to immediately supply the vaccine to the US government, with 100 million doses to be distributed in the country